Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
Kenneth G SaagNicola PannacciulliPiet GeusensJonathan D AdachiOsvaldo D MessinaJorge Morales-TorresRonald EmkeyPeter W ButlerXiang YinWillem F LemsPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2019)
Denosumab was superior to risedronate in terms of increases in spine and hip BMD through month 24, and the safety profile was similar between treatment groups. Denosumab may offer a new osteoporosis treatment option for glucocorticoid-treated patients.
Keyphrases
- bone mineral density
- double blind
- postmenopausal women
- phase iii
- placebo controlled
- clinical trial
- end stage renal disease
- phase ii
- newly diagnosed
- open label
- ejection fraction
- study protocol
- chronic kidney disease
- body composition
- mass spectrometry
- high glucose
- peritoneal dialysis
- patient reported outcomes
- replacement therapy
- oxidative stress
- liquid chromatography